

PregnanTech LTD

Website www.pregnantech.com

CEO name Dr. David Shashar \

Biotech/Pharma or Medical Devices or Health IT/Digital *

1-Executive Summary / Investment Rational PRegnanTech is a medical technology company dedicated to transforming maternal and child health outcomes through innovative solutions. Our flagship product, the LIONESS device, is poised to revolutionize the prevention and treatment of preterm birth (PTB), the most significant contributor to infant mortality and morbidity globally. With a robust market opportunity and promising clinical results, PRegnanTech is making strides in advancing its technology and forging strategic partnerships. Backed by substantial investments and a proficient management team, PRegnanTech is wellpositioned to make a meaningful impact in the healthcare industry.

2-Core Technology The LIONESS device represents a breakthrough in non-surgical PTB prevention. Featuring a smartly structured silicone ring placed with intended application tools high around the uterine cervix, LIONESS relieves pressure, maintains cervical elongation, and delays the biomechanical cascade leading to spontaneous PTB. Its unique design offers the potential to significantly reduce PTB rates, thereby addressing a critical unmet need in maternal and child health.

3-Product Profile/Pipeline PRegnanTech's pipeline includes the LIONESS device, currently undergoing advanced clinical trials to validate its efficacy in delaying PTB. After two successful pilot studies with promising results, and with the initiation of a multi-center pivotal trial in the US and strategic collaborations with key stakeholders, we are paving the way for global expansion. The market potential for LIONESS is not only substantial but also international, presenting opportunities for collaborations with healthcare organizations worldwide to drive adoption and impact.

4-Business Strategy PRegnanTech's business strategy focuses on leveraging our core technology to generate both shortterm and long-term revenues. In the short term, revenue will be generated through the sale and implementation of the LIONESS device, positioned to become the gold standard for preventing and treating PTB and thus receive reimbursement. Looking ahead, we will expand our product portfolio and market reach through strategic partnerships and collaborations. These initiatives will not only drive revenue growth but also enhance our market penetration and credibility in the healthcare industry. 4-What's Next? Moving forward, PRegnanTech will intensify our R&D efforts to

further innovate in maternal and child health. This includes advancing our product pipeline, conducting preclinical and clinical trials, and optimizing our organizational capacity. By prioritizing these initiatives, PregnanTech remains committed to driving innovation and delivering value to patients and healthcare providers worldwide.